NASDAQ$EKSO
Ekso Bionics Holdings Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Ekso Bionics reported Q4 2024 revenue of $5.1M, a net loss of $3.4M, diluted EPS of $-0.14.
For Q4 2024, Ekso Bionics reported Revenue was $5.1M, net loss was $3.4M, diluted EPS was $-0.14. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $5.1M for Q4 2024.
- Net loss $3.4M.
- Diluted EPS $-0.14.
Headline financials
Revenue & EPS history
Ekso Bionics · Revenue · Quarterly
$5.1M
Forward guidance
Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.
Tailwinds
- Pipeline progress and partnership economics.
- Cash supports near-term operating plans.
Headwinds
- Operating losses until commercial scale.
- Financing and trial outcomes affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-4.1%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-4.0%
Avg return
30 days after
23%
11 / 47 earnings
Positive
+31.9%
Q2 2018
Best reaction
-27.4%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | — | — | — | |
| Q3 2025 | -2.2% | +9.6% | -9.1% | |
| Q2 2025 | -27.4% | -23.0% | -14.1% | |
| Q1 2025 | -9.1% | -10.4% | -39.7% | |
| Q4 2024 | -1.2% | -19.9% | -13.2% | |
| Q3 2024 | -7.7% | -14.7% | -36.2% | |
| Q2 2024 | -9.1% | -9.2% | +25.0% | |
| Q1 2024 | -0.8% | +4.8% | -5.2% | |
| Q4 2023 | -20.6% | -22.6% | -27.6% | |
| Q3 2023 | -0.2% | +36.2% | +100.0% | |
| Q2 2023 | -5.6% | -11.2% | -24.5% | |
| Q1 2023 | +6.4% | +3.6% | +0.0% | |
| Q4 2022 | -4.5% | +7.1% | -6.5% | |
| Q3 2022 | -9.8% | -6.7% | -25.1% | |
| Q2 2022 | +2.9% | +7.0% | +37.4% | |
| Q1 2022 | -7.3% | -4.9% | -24.9% | |
| Q4 2021 | +6.6% | +7.9% | +26.6% | |
| Q3 2021 | +8.1% | +7.1% | -18.9% | |
| Q2 2021 | -0.2% | +4.3% | -4.3% | |
| Q1 2021 | +2.1% | -1.8% | +2.2% | |
| Q4 2020 | -10.2% | -8.8% | -21.9% | |
| Q3 2020 | -1.7% | +0.5% | +38.2% | |
| Q2 2020 | -10.9% | -13.4% | -30.2% | |
| Q1 2020 | -4.5% | -8.1% | -3.3% | |
| Q4 2019 | -19.5% | -13.7% | -32.9% | |
| Q3 2019 | -7.1% | -12.9% | -18.0% | |
| Q2 2019 | -21.2% | -23.0% | -45.1% | |
| Q1 2019 | -3.2% | -4.1% | -39.5% | |
| Q4 2018 | -0.9% | +2.1% | +7.7% | |
| Q3 2018 | +1.4% | +1.9% | -14.5% | |
| Q2 2018 | +31.9% | +44.5% | +34.1% | |
| Q1 2018 | -6.8% | -9.7% | +3.4% | |
| Q4 2017 | -13.7% | -13.1% | -10.9% | |
| Q3 2017 | -6.3% | +80.4% | +145.5% | |
| Q2 2017 | -1.6% | -1.3% | -21.4% | |
| Q1 2017 | -19.5% | -36.3% | -53.5% | |
| Q4 2016 | +0.6% | -6.1% | +0.0% | |
| Q3 2016 | +4.2% | +0.2% | +7.8% | |
| Q2 2016 | -3.1% | -2.8% | -39.5% | |
| Q1 2016 | -3.1% | — | — | |
| Q4 2015 | -1.2% | — | — | |
| Q3 2015 | -2.6% | — | — | |
| Q2 2015 | -3.6% | — | — | |
| Q1 2015 | -9.6% | — | — | |
| Q4 2014 | +1.2% | — | — | |
| Q3 2014 | +10.4% | — | — | |
| Q2 2014 | -10.4% | — | — | |
| Q1 2014 | -1.8% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro